{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Portland&page=49&state=Oregon",
    "query": {
      "state": "Oregon",
      "city": "Portland",
      "page": 49
    },
    "page_size": 10
  },
  "pagination": {
    "page": 49,
    "page_size": 10,
    "total_count": 9379,
    "total_pages": 938,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Portland&page=50&state=Oregon&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Portland&page=48&state=Oregon&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-19T00:20:03.266Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT06112379",
      "title": "A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab for Neoadjuvant/Adjuvant Treatment of Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Breast Cancer"
      ],
      "interventions": [
        {
          "name": "Dato-DXd",
          "type": "DRUG"
        },
        {
          "name": "Durvalumab",
          "type": "DRUG"
        },
        {
          "name": "Pembrolizumab",
          "type": "DRUG"
        },
        {
          "name": "Doxorubicin",
          "type": "DRUG"
        },
        {
          "name": "Epirubicin",
          "type": "DRUG"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "Carboplatin",
          "type": "DRUG"
        },
        {
          "name": "Capecitabine",
          "type": "DRUG"
        },
        {
          "name": "Olaparib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1902,
      "start_date": "2023-11-14",
      "completion_date": "2032-09-23",
      "has_results": false,
      "last_update_posted_date": "2026-10-21",
      "last_synced_at": "2026-11-19T00:20:03.266Z",
      "location_count": 58,
      "location_summary": "Daphne, Alabama • Prescott, Arizona • Jonesboro, Arkansas + 53 more",
      "locations": [
        {
          "city": "Daphne",
          "state": "Alabama"
        },
        {
          "city": "Prescott",
          "state": "Arizona"
        },
        {
          "city": "Jonesboro",
          "state": "Arkansas"
        },
        {
          "city": "Rogers",
          "state": "Arkansas"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06112379"
    },
    {
      "nct_id": "NCT03578003",
      "title": "Morning Bright Light to Improve Sleep Quality in Veterans",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Brain Injuries, Traumatic",
        "Post-traumatic Stress Disorder"
      ],
      "interventions": [
        {
          "name": "Morning Bright Light Therapy",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Portland VA Medical Center",
      "sponsor_class": "FED",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 200,
      "start_date": "2017-08-02",
      "completion_date": "2026-12-01",
      "has_results": false,
      "last_update_posted_date": "2025-11-14",
      "last_synced_at": "2026-11-19T00:20:03.266Z",
      "location_count": 1,
      "location_summary": "Portand, Oregon",
      "locations": [
        {
          "city": "Portand",
          "state": "Oregon"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03578003"
    },
    {
      "nct_id": "NCT01571427",
      "title": "Conversations as a Means to Delay the Onset of Alzheimer's Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Mild Cognitive Impairment",
        "Cognitive Change"
      ],
      "interventions": [
        {
          "name": "Active social engagement group",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Control group",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "Oregon Health and Science University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "70 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "70 Years and older"
      },
      "enrollment_count": 83,
      "start_date": "2012-02",
      "completion_date": "2013-09",
      "has_results": true,
      "last_update_posted_date": "2020-02-05",
      "last_synced_at": "2026-11-19T00:20:03.266Z",
      "location_count": 1,
      "location_summary": "Portland, Oregon",
      "locations": [
        {
          "city": "Portland",
          "state": "Oregon"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01571427"
    },
    {
      "nct_id": "NCT03005418",
      "title": "Humacyte Acellular Tissue Engineered Vessel (ATEV) in Patients With Vascular Trauma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Trauma",
        "Vascular System Injury"
      ],
      "interventions": [
        {
          "name": "Acellular Tissue Engineered Vessel (ATEV)",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Humacyte, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "18 Years to 85 Years"
      },
      "enrollment_count": 72,
      "start_date": "2018-09-01",
      "completion_date": "2026-05-15",
      "has_results": true,
      "last_update_posted_date": "2026-07-29",
      "last_synced_at": "2026-11-19T00:20:03.266Z",
      "location_count": 27,
      "location_summary": "La Jolla, California • Los Angeles, California • Orange, California + 18 more",
      "locations": [
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03005418"
    },
    {
      "nct_id": "NCT02144610",
      "title": "Efficacy and Safety of AMG0001 in Subjects With Critical Limb Ischemia",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Critical Limb Ischemia"
      ],
      "interventions": [
        {
          "name": "HGF Plasmid (AMG0001)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Matching Placebo",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "AnGes USA, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": "90 Years",
        "sex": "ALL",
        "summary": "40 Years to 90 Years"
      },
      "enrollment_count": 46,
      "start_date": "2014-11-12",
      "completion_date": "2016-11-28",
      "has_results": true,
      "last_update_posted_date": "2019-08-13",
      "last_synced_at": "2026-11-19T00:20:03.266Z",
      "location_count": 28,
      "location_summary": "Tucson, Arizona • Little Rock, Arkansas • La Jolla, California + 23 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Laguna Hills",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02144610"
    },
    {
      "nct_id": "NCT00249782",
      "title": "A Phase II, Randomized Study of ACZONE™ (Dapsone) Gel, 5% for Papulopustular Rosacea.",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Rosacea"
      ],
      "interventions": [
        {
          "name": "Vehicle control, 2x/day",
          "type": "DRUG"
        },
        {
          "name": "ACZONE (dapsone) Gel, 5%, 2x/day",
          "type": "DRUG"
        },
        {
          "name": "ACZONE (dapsone) Gel, 5%, 1x/day",
          "type": "DRUG"
        },
        {
          "name": "MetroGel® (metronidazole gel), 1.0% 1x/day",
          "type": "DRUG"
        },
        {
          "name": "ACZONE (dapsone) Gel, 5%, 1x/day (AM) + MetroGel (metronidazole gel), 1.0%, 1x/day (PM)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Allergan",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 400,
      "start_date": "2005-11",
      "completion_date": "2006-05",
      "has_results": false,
      "last_update_posted_date": "2011-05-30",
      "last_synced_at": "2026-11-19T00:20:03.266Z",
      "location_count": 26,
      "location_summary": "Birmingham, Alabama • Tucson, Arizona • Fremont, California + 21 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Fremont",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Santa Monica",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00249782"
    },
    {
      "nct_id": "NCT00317642",
      "title": "A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Acute Myelogenous Leukemia"
      ],
      "interventions": [
        {
          "name": "clofarabine (IV formulation)",
          "type": "DRUG"
        },
        {
          "name": "placebo",
          "type": "DRUG"
        },
        {
          "name": "cytarabine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Genzyme, a Sanofi Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "55 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "55 Years and older"
      },
      "enrollment_count": 326,
      "start_date": "2006-08",
      "completion_date": "2012-01",
      "has_results": true,
      "last_update_posted_date": "2014-04-14",
      "last_synced_at": "2026-11-19T00:20:03.266Z",
      "location_count": 41,
      "location_summary": "Scottsdale, Arizona • Tucson, Arizona • Little Rock, Arkansas + 34 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00317642"
    },
    {
      "nct_id": "NCT00053417",
      "title": "Safety and Efficacy Study of Oral Fampridine-SR in Patients With Multiple Sclerosis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Multiple Sclerosis"
      ],
      "interventions": [
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "10 milligram (mg) fampridine-SR (4-aminopyridine, 4-AP)",
          "type": "DRUG"
        },
        {
          "name": "15 mg fampridine-SR (4-aminopyridine, 4-AP)",
          "type": "DRUG"
        },
        {
          "name": "20 mg fampridine-SR (4-aminopyridine, 4-AP)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Acorda Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 206,
      "start_date": "2003-02",
      "completion_date": "2003-12",
      "has_results": true,
      "last_update_posted_date": "2011-08-04",
      "last_synced_at": "2026-11-19T00:20:03.266Z",
      "location_count": 23,
      "location_summary": "Phoenix, Arizona • Los Angeles, California • New Haven, Connecticut + 19 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00053417"
    },
    {
      "nct_id": "NCT05108623",
      "title": "A Study Investigating agenT-797 in Participants With Relapsed/Refractory Solid Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Tumor, Solid"
      ],
      "interventions": [
        {
          "name": "agenT-797",
          "type": "DRUG"
        },
        {
          "name": "Approved ICIs",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "MiNK Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 34,
      "start_date": "2022-01-28",
      "completion_date": "2024-01-02",
      "has_results": false,
      "last_update_posted_date": "2024-04-24",
      "last_synced_at": "2026-11-19T00:20:03.266Z",
      "location_count": 8,
      "location_summary": "Los Angeles, California • Aurora, Colorado • Louisville, Kentucky + 5 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Louisville",
          "state": "Kentucky"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Cincinnati",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05108623"
    },
    {
      "nct_id": "NCT00978562",
      "title": "DSC-MRI With Ferumoxytol and DCE-MRI With Gadolinium in Imaging Vascular Properties in Younger Patients With Brain Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Childhood Brain Neoplasm",
        "Recurrent Childhood Brain Neoplasm"
      ],
      "interventions": [
        {
          "name": "Dynamic Contrast-Enhanced Magnetic Resonance Imaging",
          "type": "PROCEDURE"
        },
        {
          "name": "Dynamic Susceptibility Contrast-Enhanced Magnetic Resonance Imaging",
          "type": "PROCEDURE"
        },
        {
          "name": "Ferumoxytol Non-Stoichiometric Magnetite",
          "type": "DRUG"
        },
        {
          "name": "Gadolinium",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "DRUG"
      ],
      "sponsor": "OHSU Knight Cancer Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "5 Years",
        "maximum_age": "18 Years",
        "sex": "ALL",
        "summary": "5 Years to 18 Years"
      },
      "enrollment_count": 14,
      "start_date": "2009-08",
      "completion_date": "2018-12",
      "has_results": true,
      "last_update_posted_date": "2022-08-03",
      "last_synced_at": "2026-11-19T00:20:03.266Z",
      "location_count": 1,
      "location_summary": "Portland, Oregon",
      "locations": [
        {
          "city": "Portland",
          "state": "Oregon"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00978562"
    }
  ]
}